Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
Timothy SpelmanLars ForsbergKyla McKayAnna GlaserJan HillertPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)
Rituximab treatment, known to increase the risk of severe infections in general, also confers such a risk for MS patients with COVID-19, in comparison with other MS DMTs.
Keyphrases
- multiple sclerosis
- end stage renal disease
- newly diagnosed
- white matter
- diffuse large b cell lymphoma
- mass spectrometry
- coronavirus disease
- ejection fraction
- sars cov
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- hodgkin lymphoma
- early onset
- patient reported outcomes
- combination therapy
- replacement therapy